SCHEMBL23254754

SCHEMBL23254754

CC(C)(C)OC(=O)NCCOCCOCCNC(=O)c1ccc(CCl)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.44
IDO1 P14902 1/20 0.44
SUCNR1 Q9BXA5 1/20 0.43
CA2 P00918 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HPGD P15428 1/20 0.43
NAMPT P43490 1/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA9 Q16790 2/20 0.42
DGAT1 O75907 1/20 0.41
ESRRG P62508 1/20 0.41
POLB P06746 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
KMT2A Q03164 1/20 0.41
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23254969 0.99 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1IDO1SUCNR1CA2
SCHEMBL12261006 0.94 HPGD (0.51) SMN1; SMN2ALDH1A1CA2NPC1RAB9A
SCHEMBL7891123 0.91 DGAT1 (0.47) SMN1; SMN2ALDH1A1CA2NPC1RAB9A
SCHEMBL6674215 0.88 SMN1; SMN2 (0.50) SMN1; SMN2IDO1SUCNR1CA2NAMPT
SCHEMBL21674211 0.87 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1CA2NPC1RAB9A
SCHEMBL4257896 0.86 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1IDO1SUCNR1CA2
SCHEMBL22939679 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1IDO1CA2NPC1
SCHEMBL22938995 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1IDO1CA2NPC1
SCHEMBL22939048 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1IDO1CA2NPC1
SCHEMBL22939676 0.85 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1IDO1CA2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595318-B2 2026-04-07 US disclosed
US-20240174772-A1 NOVEL CROSSLINKED ALGINIC ACID MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2024-05-30 US disclosed
US-11932708-B2 Crosslinked alginic acid MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2024-03-19 US disclosed
WO-2021125279-A1 CHEMICALLY CROSSLINKED ALGINATE GEL FIBER 持田製薬株式会社 2021-06-24 WO disclosed
EP-3808783-A1 NOVEL CROSSLINKED ALGINIC ACID Mochida Pharmaceutical Co., Ltd. (JP) 2021-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595318-B2 ALG1, ALG8, FUCA1 SMN1; SMN2 4073/4885ALDH1A1 1277/4885IDO1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.